New Pharmaceutical Report Highlights how Organizations can Improve the Development of Combination Products

Saturday, September 29, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

CHAPEL HILL, N.C., Sept. 28, 2018 /PRNewswire/ -- A growing number of medical therapies currently in development are combination

products that incorporate drug, biologic and/or medical device components.

The pharmaceutical industry recognizes the potential value of attacking complex diseases such as cancer through new therapies that utilize combinations of FDA-approved

products. However, the path from design and development to filing and approval for these products is not straightforward and comes with a daunting set of complexities. Some of these challenges include simultaneously developing a drug and device for testing and working with external vendors for materials and manufacturing.

To help organizations navigate the shifting landscape of combination product development, research and consulting leader Best Practices, LLC conducted a new study to provide insights into how healthcare companies can improve the way they develop and launch combination products.

"Leading in the Combination Product Space: Insights for Improving the External Engagement, and Internal Development and Management" is a 44-page study that will inform product and leadership teams about:

  • Key external engagement approaches
  • Development phases and decision points
  • Timing, staffing and investment
  • Partner management
  • IP protection

Seventeen executives from 14 leading pharma, biotechnology and other healthcare companies participated in this research through a benchmarking survey and executive interviews.

The research found that Intellectual Property (IP) protection is a major concern and it is imperative to involve legal departments in combination partnerships. Combination product partnerships present real IP risks to most drug manufacturers. Among the concerns cited by benchmark partners were: Infringement, reverse engineering, IP ownership, confidentiality of external partners, and lack of proactive legal expertise. Industry counterparts suggested the following steps to reduce risk and protect assets: adopt a proactive approach with legal expertise in patenting, vetting and contracting with partners; use non-disclosure agreements; use firewalls to prevent reverse engineering; and include legal experts even in technical discussions with device partners.

Best Practices, LLC conducted this study to help pharma and biotech companies improve the way they develop, manage and commercialize new combination products.

To learn more about this report, download a complimentary report excerpt at http://www.best-in-class.com/rr1513.htm.

For related research, visit our Best Practices, LLC Web site at www.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.

 

Cision View original content:http://www.prnewswire.com/news-releases/new-pharmaceutical-report-highlights-how-organizations-can-improve-the-development-of-combination-products-300721139.html

SOURCE Best Practices, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store